Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is one of the stocks on Jim Cramer’s radar recently. During the lightning round, ...

We came across a bullish thesis on Catalyst Pharmaceuticals, Inc. on BioEquity Watch’s Substack. In this article, we will ...

Shares of Catalyst Pharmaceuticals Inc. CPRX slid 3.75% to $22.35 Tuesday, on what proved to be an all-around dismal trading ...

If you are wondering whether Catalyst Pharmaceuticals' current share price still reflects a good entry point, or if the best ...

For most investors, how much a stock's price changes over time is important. Not only can it impact your investment portfolio, but it can also help you compare investment results across sectors and ...

Catalyst Pharmaceuticals Inc. closed 12.83% short of its 52-week high of $26.58, which the company achieved on June 9th.

(RTTNews) - Commercial-stage biopharmaceutical company Catalyst Pharmaceuticals, Inc. (CPRX), Wednesday announced a new share repurchase program to repurchase up to $200 million of shares of ...

“We are honored to once again be recognized on Forbes’ list of America’s Most Successful Small-Cap Companies for 2026,” said Rich Daly, President and CEO, Catalyst. “Our accomplishments over the past ...

Catalyst Pharmaceutical (CPRX) came out with quarterly earnings of $0.68 per share, beating the Zacks Consensus Estimate of $0.51 per share. This compares to earnings of $0.57 per share a year ago.